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Esophageal varices are the major complication of portal hypertension. It is detected in about 50% of cirrhosis patients, and
approximately 5–15% of cirrhosis patients show newly formed varices or worsening of varices each year. The major therapeutic
strategy of esophageal varices consists of primary prevention, treatment for bleeding varices, and secondary prevention, which
are provided by pharmacological, endoscopic, interventional and surgical treatments. Optimal management of esophageal varices
requires a clear understanding of the pathophysiology and natural history. In this paper, we outline the current knowledge and
future prospect in the pathophysiology of esophageal varices and portal hypertension.
1.Introduction
Esophageal varices are the major complication of portal
hypertension. It is detected in about 50% of cirrhosis
patients, and approximately 5–15% of cirrhosis patients
show newly formed varices or worsening of varices each year
[1–5]. It is a hemodynamic abnormality characterized by
sudden bleeding episode; about a third of all patients with
esophageal varices show bleeding episode [6].
A key objective in managing the cirrhotic patients
having varices is the primary prevention of bleeding. Either
nonselective β-blockers or endoscopic variceal ligation is the
treatments of choice for the primary prevention of variceal
bleeding [7]. Patients who survive an episode of variceal
bleeding are at high risk for rebleeding. Combination of β-
blockers and band ligation is the preferred therapy to reduce
rebleeding rate [7]. Failures of medical treatment should
be managed aggressively with transjugular intrahepatic
portosystemic shunting (TIPS), preferably using expanded
polytetraﬂuoroethylene (ePTFE) covered stents [7]. Because
of higher rates of morbidity and mortality, rescue derivative
surgery should only be considered in low-risk patients.
Optimal management of esophageal varices requires a
clear understanding of the pathophysiology and natural
history. In this paper, we outline the current knowledge and
future prospect in the pathophysiology of esophageal varices
and portal hypertension.
2. Pathophysiology of Portal Hypertension and
Esophageal Varices
Portal hypertension is associated with both increased portal
inﬂow and increased outﬂow resistance [8]. Although direct
measurementof portal pressure may provide accuratecondi-
tion, an invasiveness of portal venous catheterization limits
the clinical application. Hepatic venous catheterization is the
most common technique to determine the portal pressure.
Wedged hepatic venous pressure (WHVP) reﬂects sinusoidal
pressures, and hepatic venous pressure gradient (HVPG)
is the diﬀerence between WHVP and free hepatic venous
pressure, being a good predictor for the severity of portal
hypertension.Portalhypertensionresultsinthedevelopment
of collateral vessels, which are the route blood returning to
the systemic circulation from portal system bypassing the
liver.
3. NaturalHistoryandBleeding Risks of
Esophageal Varices
Varices may not develop and bleed when the HVPG is lower
than 12mmHg [5, 9]. That is, varices are closely associated2 International Journal of Hepatology
withthe condition of HVPG higher than 12mmHg. Red sign
and variceal size (medium to large grade) on endoscopy are
representative for bleeding risk of esophageal varices [7, 10].
Severity of liver function reserve and presence of ascites are
also important risk factors for variceal bleeding [10].
The bleeding risk decreases over time from the time that
varices are identiﬁed; most bleeding episodes occur within
the ﬁrst 2 years after identiﬁcation of varices [6]. Once
bleeding occurs, spontaneous cessation of bleeding occurs in
only up to 40% of individuals, and the bleeding is associated
with the mortality of 20% or more at 6 weeks [11, 12].
Patients who survived an episode of acute variceal
hemorrhage have a high risk of rebleeding and death [13].
The median rebleeding rate in untreated individuals is
around 60% within 1-2 years of the index bleeding, with a
mortality of 33% [14, 15]. Therefore, care should be taken
to prevent recurrent bleeding prior to discharge from the
hospital for patients who have recovered from an episode of
variceal bleeding.
Patients with an HVPG > 20mmHg measured within 24
hours of variceal bleeding have been identiﬁed as being at a
higher risk for early rebleeding or failure to control bleeding
(83% versus 29%) and a higher 1-year mortality (64% versus
20%) compared to those with lower pressure [16, 17]. Large
varices, age over 60 years’ old, renal failure, and severe initial
bleeding as deﬁned by a hemoglobin <8g/dL at admission,
are the risk factors for early rebleeding [6].
4. Pathophysiology of Portal Hypertension and
Esophageal Varices
4.1. Hepatic Vasodilators
(1) Nitric Oxide. Nitric oxide (NO) is a powerful endoge-
nous vasodilator (Table 1), and it modulates the intrahepatic
vascular tone [18]. NO is produced from the amino acid l-
arginine by NO synthases. It is the natural ligand for soluble
guanylate cyclase and is responsible for an increase in the
levels of cyclic guanosine monophosphate, the ﬁnal agent
responsible for the relaxation of the vascular wall through
the extrusion of cytosolic Ca2+.
NO inhibition increases portal pressure in isolated per-
fused rat livers, and the hepatic response to norepinephrine
is markedly enhanced after NO inhibition, suggesting a
role of NO in modulating hepatic vascular tone in normal
conditions [18]. However, in the cirrhotic liver, the synthesis
ofNOisinsuﬃcienttocompensatefortheactivationofvaso-
constrictor systems frequently associated with cirrhosis. This
occurs despite a normal expression of eNOS (endotherail
NO synthase) mRNA and normal levels of eNOS protein
[19], and the decreased activity of hepatic eNOS in cirrhosis
is due in part to increased expression of caveolin [20]; as
Akt-induced phosphorylation of eNOS reverses inhibitory
conformation of eNOS in association with caveolin-1 [21].
The insuﬃcient hepatic NO production may account for
the increased intrahepatic vascular resistance in cirrhosis,
thereby worsening portal hypertension. These ﬁndings may
be supported by the data; the infusion of l-arginine, the
Table 1: Vasoactive mediators.
Vasodilators Vasoconstrictors
Nitric oxide Endothelin
Carbon monoxide Angiotensin II
Glucagon Norepinephrine
Endocannabinoid Vasopressin
Prostaglandin
precursor of NO biosynthesis, and the administration of
nitrates (exogenous donors of NO) decrease portal pressure.
Further, enhancement of the expression of NO synthase in
livercells,throughtheportalinjectionofadenoviruscoupled
with the gene encoding NO synthase, signiﬁcantly reduces
portal pressure.
Recent study has shown that myr-Akt gene therapy
restored Akt activation and NO production in the cirrhotic
liver, suggesting the potential availability of alternative treat-
ment for portal hypertension [22]. The other study reported
that simvastatin stimulated hepatosplanchnic output of NO
products and decreases hepatic resistance in cirrhosis due
to the increased Akt-dependent endothelial NO synthase
phosphorylation [23]. The data was supported clinically by
the randomized controlled trial [24]. NO also promotes
apoptosis of hepatic stellate cell through a signaling mech-
anism that involves mitochondria, is mediated by reactive
oxygen species, and occurs independent of caspase activation
[25]. This NO-dependent apoptosis, which may maintain
sinusoidal homeostasis, is expected as a future treatment of
portal hypertension.
(2) Carbon Monoxide. Carbon monoxide (CO), a by-
product of heme group oxidation by heme oxygenases
(HOs), is considered as an important modulator of intra-
hepatic vascular resistance [26]. CO activates guanylate
cyclase and thereby promotes smooth muscle relaxation, in
spite of being less potent than NO. The inhibition of CO
production increases portal resistance in normal livers, and
HO/CO system is activated in patients with liver cirrhosis. In
addition, plasma CO levels directly correlated with cardiac
output and inversely with systemic vascular resistance and
mean arterial pressure. Thus, CO may be closely related to
the hyperdynamic circulatory state in cirrhosis [27].
4.2. Splanchnic Vasodilatation. Portal venous inﬂow tends
to increase in cirrhosis, particularly in advanced stages
of portal hypertension, due to the vasodilatation in the
splanchnic organ. This increased blood ﬂow is one of the
keyfactorswhichcontributetothepathophysiologyofportal
hypertension [28]. There are some possible mechanisms
which account for the portal hemodynamic abnormalities,
neurogenic, humoral, and local mechanisms; vasodilators
in the systemic circulation have been examined to explain
the pathophysiology of portal hypertension. Increased levels
of vasodilators are observed because of impaired hepatic
function or development of portosystemic collaterals, as
most of them underwent hepatic metabolisms.International Journal of Hepatology 3
(1) NO. NO is involved in the regulation of splanchnic and
systemic hemodynamics in portal hypertension. Excessive
production of NO may be one of major reasons for the
vasodilatation, as splanchnic vasoconstrictive eﬀect caused
by NO inhibitors in animal is signiﬁcantly greater in
portal hypertension model than control model [29]. An
overproduction of NO has also been clearly demonstrated
in vitro in perfused mesenteric artery preparations from
portal hypertensive rats [18]. Furthermore, the fact that
cirrhotic patients show increased levels of serum and urinary
concentrations of nitrite and nitrate, which are products
of NO oxidation, also supports a role of NO in the
pathophysiology of portal hypertension [30]. An increased
expression and an increased activity of eNOS account for
the increased production of NO. Further, there are some
factors which may activate the constitutive NO synthase:
shear stress, circulating vasoactive factors (e.g., endothelin,
angiotensin II, vasopressin, and norepinephrine), and over-
expression of the angiogenic factor vascular endothelial cell
growth factor (VEGF) [31]. Recent study suggests that mild
increases of portal pressure upregulate eNOS at the intestinal
microcirculation through VEGF upregulation [32].
(2) Glucagon. Glucagon is a humoral vasodilator which is
associated with splanchnic hyperemia and portal hyper-
tension. Two mechanisms are considered for vasodilation
by glucagon; relaxing the vascular smooth muscle and
decreasing its sensitivity to endogenous vasoconstrictors,
such as norepinephrine, angiotensin II, and vasopressin
[33]. Plasma glucagon levels are increased in cirrhotic
patients and experimental models of portal hypertension,
due to decreased hepatic clearance of glucagon as well as an
increased secretion of glucagon by pancreatic α cells [34].
Administration of glucagon antibodies or somatostatin
reverses the increase in splanchnic blood ﬂow as a result
of normalizing circulating glucagon levels. Additionally,
concomitant infusion of glucagon blocks the response in
portal hypertensive rat model, and increased circulating
glucagon levels in normal rats to values similar to those
observed in portal hypertension cause a signiﬁcant increase
in splanchnic blood ﬂow [35, 36]. According to these data,
hyperglucagonemia may be responsible for some part of
thesplanchnicvasodilatationofchronicportalhypertension.
The role of glucagon in the splanchnic hyperemia of portal
hypertension provides a rationale for the use of somatostatin
and its synthetic analogs to reduce glucagon level, thereby
treating portal hypertension [37].
(3) Other Mediators. CO is one of the vasodilators; an
expression and activity of HO are increased in splanchnic
tissuesinportalhypertension[27].HOalsostimulatesVEGF
production, resulting in the development of hyperdynamic
splanchnic circulation [38].
Recent study has shown that endocannabinoids have a
signiﬁcant role in the hyperdynamic circulation of portal
hypertension [39]. Endogenous cannabinoid anandamide is
increased in the monocyte fraction of blood from cirrhotic
humans and rats, and also expression of the cannabinoid 1
(CB1) receptors is increased in hepatic human endothelial
cells. It is considered that activation of endothelial CB1
receptors may stimulate NO production, though the mech-
anism is unclear. Therefore, inhibition of CB1 receptor
blockade may have a possibility of treatment for portal
hypertension as a result of reduction of portal ﬂow.
Prostacyclin is an endogenous vasodilator produced by
vascular endothelial cells [40]. It causes vascular smooth
muscle relaxation by activating adenylate cyclase and aug-
menting the intracellular level of cyclic adenosine mono-
phosphate. Two diﬀerent isoforms of cyclooxygenase COX
are involved in the biosynthesis of prostacyclin, COX1 and
COX2. Both are involved in the increased prostacyclin
production by the mesenteric vascular bed of portal vein-
ligated rats and the selective inhibition of COX-2 and, to a
lesser extent of COX-1, improve the endothelial-dependent
vasodilatation in response to acetylcholine [41]. A partial
reversal eﬀect for splanchnic vasodilatation after COX block-
ade might be applicable to ameliorate the hyperdynamic
circulation state and/or portal pressure in cirrhosis.
4.3. Hyperdynamic Circulation. T h ep o r t a lh y p e r t e n s i o ni s
directly related to portal inﬂow and/or outﬂow resistance,
as determined by Ohm’s law “portal pressure = portal
venous inﬂow × outﬂow resistance.” Portal venous inﬂow is
aﬀected by hyperdynamic circulation, which is characterized
by systemic and splanchnic vasodilatation, low systemic
resistance, plasma volume expansion, and high cardiac index
[8]. Splanchnic vasodilatation contributes to increasing
substantial blood volume which returns to portal venous
system. Peripheral vasodilatation activates endogenous neu-
rohumoral systems that cause sodium retention, which leads
to expansion of the plasma volume, followed by an increase
in the cardiac index. Expansion of plasma volume is a
necessary step to maintain an increased cardiac index, which
in turn aggravates portal hypertension. This provides the
rationale for using a low-sodium diet and diuretics in the
treatment of portal hypertension.
4.4. Portosystemic Collateral Circulation. The development
of portal-collateral circulation is one of the hemodynamic
features of portal hypertension. Formation of collaterals is
a complex process involving the opening, dilatation, and
hypertrophy of preexisting vascular channels. Collaterals
develop according to the increased portal pressure, and
minimum threshold level of HVPG may be 10mmHg for
the development of portosystemic collaterals and esophageal
varices [5, 9].
The vascular resistance of collateral vessels may be a
major component of the overall resistance to portal blood
ﬂow and, therefore, may be important in determining
portal pressure. In addition, although it was traditionally
thought that the hyperdynamic splanchnic circulation state
associated with portal hypertension was the consequence of
active splanchnic vasodilatation, recent data suggests that
the increased neovascularization in splanchnic organs plays
an important role in allowing the increase in splanchnic4 International Journal of Hepatology
blood inﬂow [42]. In addition to the increased portal pres-
sure, formation of portosystemic collateral vessels in portal
hypertension is inﬂuenced by a VEGF-dependent angiogenic
process and can be markedly attenuated by interfering
with the VEGF/VEGF receptor-2 signaling pathway. This
ﬁnding suggests that manipulation of the VEGF may be of
therapeutic value.
Although the factors which modulate the resistance
of collateral vessels have not been clariﬁed, NO may be
one of the factors which regulate portal collateral vascular
resistance [43]. Eﬀects of isosorbide-5-mononitrate (IMN)
and nitroglycerin (NTG) to reduce collateral resistance in
cirrhosis may be associated with this NO function. These
vessels are also probably hypersensitive to serotonin (5-
HT), which markedly increases their vascular tone. In portal
hypertensive animals, the administration of selective 5-HT2
receptor blockers decreases portal pressure.
4.5. Vasoconstrictors and Hepatic Vascular Bed. Endothelins
(ETs) are a family of homologous 21 amino acid peptides
which include ET-1, -2, -3, and -4. They exert various
biological eﬀects, vasoconstriction, and stimulation of cell
proliferation in tissue. One of the major roles of ET is
modulation of vascular tone in cirrhosis [44]. Two major
receptors function to mediate, ET-A receptor and ET-
Br e c e p t o r .T h ef o r m e rs h o w sah i g ha ﬃnity for ET-1,
not for ET-3, and mediates constriction, and the latter
has equal aﬃnity for ET-1 and ET-3. Activation of ET-B
receptors located on the vascular smooth muscle cells pro-
motesvasoconstriction,whereasactivationofET-Breceptors
located on endothelial cells promotes vasodilatation, which
is mediated by enhanced NO and prostacyclin production by
the endothelial cell.
Plasma levels of ET-1 and ET-3 are increased in cirrhotic
patients [45]. The level is dominant in patients with ascites.
A net release of ET-1 and ET-3 in the splanchnic circulation
has been observed in cirrhotic patients but not in controls,
suggestinganincreasedproductionofET-1andET-3.Infact,
increased expression of ET-1 is reported in human cirrhotic
livers [46]; endothelial cells, hepatic stellate cells (in their
activated phenotype), and bile duct epithelial cells are the
major intrahepatic sources of ET-1. However, the precise
mechanism and role of ETs in increasing the vascular tone
in cirrhosis remains unclear.
Angiotensin II is a powerful vasoconstrictor, which
may contribute to increasing hepatic resistance [47]. A-II
antagonists, inhibitors of the converting enzyme, or A-II
receptors blockers may have a potential to reduce portal
pressure, though their eﬀects may be accompanied with
systemic hypotension.
Norepinephrine is also a vasoconstrictor, which is
involved in the regulation of hepatic vascular tone [48, 49].
The administration of α-adrenergic antagonists, such as pra-
zosin, inhibits the increase of resistance by norepinephrine.
In addition, the hepatic vascular bed of cirrhotic livers
exhibits an exaggerated response to the α-adrenergic agonist
methoxamine. This hyperresponse is associated with the
overproductionofthromboxaneA2 (TXA2)byCOX-1isoen-
zyme and is completely corrected by pretreating the livers
with nonselective COX blockers, COX-1-selective blockers,
or TXA2 antagonists. Therefore, an increased production
of TXA2 markedly enhances the vasoconstrictive response
of the cirrhotic hepatic vascular bed to methoxamine. It
remains to be solved, however, that whether this eﬀect is also
shared by other vasoconstrictors.
4.6. Endothelial Dysfunction. The endothelium under nor-
mal condition has a function to produce vasodilators in
response to increases in blood volume and blood pressure
or to produce vasoconstrictors to prevent or attenuate the
concomitant increase in pressure. However, abnormality in
the endothelium-related vascular reaction occurs in sev-
eral pathologic conditions, that is, endothelial dysfunction
[50]. It is considered as one of the main mechanisms
which account for the increased vascular tone observed
in several vascular disorders, such as arterial hypertension,
diabetes, and atherosclerosis, and have been attributed to
a diminished NO bioavailability or to an increased pro-
duction of endothelial-derived contracting factors, such as
prostaglandin H2 (PGH2)/TXA2, ET, or anion superoxide
[18]. The intrahepatic vascular bed in cirrhosis also exhibits
endothelial dysfunction [51]. Indeed, studies performed
both in cirrhotic patients and in experimental models
have shown that, contrary to what happens in normal
livers, the cirrhotic liver cannot accommodate the increased
portal blood ﬂow caused by the postprandial hyperemia,
which determines an abrupt postprandial increase in portal
pressure [52].
Studies have shown that endothelial dysfunction is
associated with an abnormal response to the endothelium-
dependent vasodilator acetylcholine [51, 53]. This impaired
response may be related to an increased production of TXA2
and completely prevented by selective COX-1 blockers and
TXA2 antagonists. These data suggest that an increased
production of a COX-1-derived vasoconstrictor prostanoids,
probably TXA2, may be responsible for endothelial dysfunc-
tion [53].
Recent studies have shown the possibilities of additional
treatments; one is tetrahydrobiopterin, an eNOS cofactor,
which increases eNOS activity and signiﬁcantly improves the
vasodilator response to acetylcholine in rats with cirrhosis
[54]. It may have a potential role for the treatment of
portal hypertension by improving the endothelial dysfunc-
tion. The other is “statins,” which decreases intrahepatic
vascular resistance and improve ﬂow-mediated vasodilation
of liver vasculature in cirrhotic liver, due to increase of
NO production and improvement of hepatic endothelial
dysfunction [23, 24].
5. Conclusions
Many advances in the management of portal hypertension
and variceal bleeding have occurred over the last 20 years.
The key factor for variceal rupture is the wall tensionInternational Journal of Hepatology 5
Sequence of the events
in patients with chronic liver disease
Chronic inﬂammation
Portal hypertension
Hepatic ﬁbrosis
Splenomegaly
Increase of portal venous pressure
Development of collateral vessels
Variceal bleeding
Hepatic encephalopathy
Ascites
Figure 1: Sequence of the events in patients with chronic liver
diseases. Possible events are listed from chronic inﬂammation to
portal hypertension.
of varices, which is determined by the “Lapace’s law”:
wall tension = (variceal pressure – luminal pressure) ×
radius/thickening of variceal wall. This tension is the force
which is generated by the variceal wall opposing further
distension. When the wall tension reaches the critical point
of the elastic limit of the varices, rupture occurs. Red sign
on endoscopy is a signiﬁcant indicator to apply prophylactic
treatment of esophageal varices. Eﬀective primary preven-
tion for variceal bleeding is now available by nonselective
beta blockers or band ligation. Active bleeding should be
managedwithbandligationaloneorcombinedwithsomato-
statin or octreotide; TIPS and surgery may be positioned
as salvage therapy for those who fail endoscopic treatment.
Survivors of a variceal bleed should be evaluated for liver
transplant.
Since the occurrence of clinical events due to portal
hypertension is related to the hemodynamic changes (Fig-
ure 1), the goal of long-term pharmacologic therapy in
patients with portal hypertension should be a reduction
of the HVPG by at least 20% from baseline values and
preferably to below the threshold of 12mmHg. This may
explain some of the interindividual variability in hemody-
namic response to pharmacological treatment. Recent study
has shown that rifaximin may have a possibility to decrease
risk of variceal bleeding, and the other complications related
to portal hypertension [55]. The pathophysiology in portal
hypertension is likely to be multifactorial in origin; various
interactive regulations may be present to compensate for the
eﬀect of vasoactive mediators. It is a continuous challenge
to unveil the mechanism and to develop more eﬀective
therapeutic measures.
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